Rentokil Initial shares rose 2.3% to 455.1 pence in the session following a rating change from Goldman Sachs, which upgraded the pest control and hygiene services group from Neutral to Buy. The bank also raised its 12-month price target to 590 pence from 515 pence - a level Goldman said implies roughly 33% upside from the prior close of 444.7 pence.
Goldman Sachs signalled confidence in the company’s trajectory by highlighting a steady improvement in North American organic growth that it says began in the third quarter of 2025. The broker projects this trend to continue, with a return to mid-single-digit organic growth by 2027. In Goldman’s view, those dynamics — together with the present valuation — make the shares an appealing entry point for investors.
The upgrade followed a period of stock weakness. Shares had declined by about 12% since Rentokil’s first-quarter results, despite the company reporting encouraging top-line momentum. In Q1 2026 the group recorded organic revenue growth of 3.4% overall, with North America delivering 3.9% organic growth, data cited by the research note show.
Goldman’s reassessment framed the previous sell-off as an overcorrection by the market. The bank’s revised rating and higher target established a clearer upside scenario for investors at a time when the company also announced management changes in its North America business. The recent appointment of a new North America CEO was cited as reinforcing the narrative that operational improvement is gaining traction.
Market context provided modest support for the move. On July 7, 2026 the FTSE 100 opened marginally higher after a slight decline in the prior session, with sentiment described as cautiously optimistic as geopolitical risk premia eased. U.S. markets were trading positively in parallel, with the S&P 500 up 0.7% and the Nasdaq higher by 1.1%, contributing to a broadly constructive tone for risk assets.
Despite the intraday gain, Rentokil was still trading below both Goldman’s new 590 pence target and its 52-week high of 506.8 pence. The upgrade therefore acted as a catalyst for a re-rating thesis centred on improving North American fundamentals and a share price that Goldman judged to have fallen beneath fair value.
In summary, the combination of an analyst upgrade, a stronger near-term operational story in North America and a management change provided the immediate impetus for the stock’s rise. Investors moved quickly to price in the defined upside case put forward by Goldman Sachs, bringing renewed attention to Rentokil’s recovery path.